NASDAQ:SVRA Savara (SVRA) Stock Forecast, Price & News $2.90 -0.03 (-1.02%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.81▼$2.9650-Day Range$1.69▼$2.9352-Week Range$1.08▼$3.01Volume363,493 shsAverage Volume342,994 shsMarket Capitalization$330.80 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Savara MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside20.7% Upside$3.50 Price TargetShort InterestBearish1.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 5 Articles This WeekInsider TradingAcquiring Shares$225,636 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.30) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector631st out of 983 stocksPharmaceutical Preparations Industry313th out of 486 stocks 2.5 Analyst's Opinion Consensus RatingSavara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Savara has a forecasted upside of 20.7% from its current price of $2.90.Amount of Analyst CoverageSavara has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.50% of the float of Savara has been sold short.Short Interest Ratio / Days to CoverSavara has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Savara has recently increased by 2.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSavara does not currently pay a dividend.Dividend GrowthSavara does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SVRA. Previous Next 3.0 News and Social Media Coverage News SentimentSavara has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Savara this week, compared to 2 articles on an average week.Search Interest7 people have searched for SVRA on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Savara to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Savara insiders have bought more of their company's stock than they have sold. Specifically, they have bought $225,636.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.57% of the stock of Savara is held by insiders.Percentage Held by Institutions75.51% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Savara are expected to grow in the coming year, from ($0.30) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Savara is -10.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Savara is -10.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSavara has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Savara (NASDAQ:SVRA) StockSavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Read More Receive SVRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter. Email Address SVRA Stock News HeadlinesJune 2, 2023 | finance.yahoo.comSavara to Present at the Jefferies Healthcare ConferenceMay 29, 2023 | americanbankingnews.comSavara Inc (NASDAQ:SVRA) Director Purchases $128,000.00 in StockJune 3, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.May 28, 2023 | finance.yahoo.comIndependent Director of Savara David Ramsay Buys 4.8% More SharesMay 28, 2023 | finance.yahoo.comIndependent Director of Savara David Ramsay Buys 4.8% More Shares \May 28, 2023 | americanbankingnews.comSavara Inc (NASDAQ:SVRA) Director David A. Ramsay Acquires 37,124 SharesMay 19, 2023 | americanbankingnews.comSavara Inc (NASDAQ:SVRA) to Post Q2 2023 Earnings of ($0.08) Per Share, HC Wainwright ForecastsMay 19, 2023 | americanbankingnews.comSavara (NASDAQ:SVRA) Upgraded at Jefferies Financial GroupJune 3, 2023 | Legacy Research (Affiliate) (Ad)From -60% Account to Doubling His Money?After helping his readers double their money 13 TIMES in the last year alone… There’s ONE person trader Jeff Clark has NOT been able to help! His 23-year-old son, Grant.May 17, 2023 | msn.comHC Wainwright & Co. Reiterates Savara (SVRA) Buy RecommendationMay 17, 2023 | markets.businessinsider.comSavara (SVRA) Gets a Buy from H.C. WainwrightMay 16, 2023 | msn.comWhy Shares of Savara Jumped on TuesdayMay 16, 2023 | msn.comSavara rises as Jefferies upgrades citing 100% upsideMay 15, 2023 | finance.yahoo.comSavara Reports First Quarter Financial Results and Provides Business UpdateMay 8, 2023 | americanbankingnews.comComparing Savara (NASDAQ:SVRA) and Pacira BioSciences (NASDAQ:PCRX)April 7, 2023 | americanbankingnews.comSavara (NASDAQ:SVRA) Rating Reiterated by HC WainwrightApril 6, 2023 | americanbankingnews.comSavara (NASDAQ:SVRA) Stock Rating Reaffirmed by HC WainwrightApril 6, 2023 | americanbankingnews.comSavara Inc (NASDAQ:SVRA) to Post Q1 2023 Earnings of ($0.07) Per Share, HC Wainwright ForecastsApril 4, 2023 | msn.comJefferies Downgrades Savara (SVRA)April 4, 2023 | americanbankingnews.comSavara (NASDAQ:SVRA) Downgraded by Jefferies Financial Group to "Hold"April 3, 2023 | finance.yahoo.comSavara Inc. (NASDAQ:SVRA) Is Expected To Breakeven In The Near FutureMarch 30, 2023 | finance.yahoo.comSavara Reports Fourth Quarter / Year-End 2022 Financial Results and Provides Business UpdateMarch 6, 2023 | finance.yahoo.comSavara to Present at the Oppenheimer 33rd Annual Healthcare ConferenceFebruary 15, 2023 | finance.yahoo.comSavara Inc. (NASDAQ:SVRA) insiders placed bullish bets worth US$858k in the last 12 monthsFebruary 14, 2023 | finance.yahoo.comSavara Announces New Leadership AppointmentsJanuary 5, 2023 | finance.yahoo.comPrivate equity firms are Savara Inc.'s (NASDAQ:SVRA) biggest owners and were rewarded after market cap rose by US$25m last weekNovember 22, 2022 | finance.yahoo.comSavara Announces New Employment Inducement GrantSee More Headlines SVRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SVRA Company Calendar Last Earnings3/30/2023Today6/03/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webwww.savarapharma.com Phone512-614-1848Fax858-552-0876EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$4.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+20.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,150,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.95% Return on Assets-28.17% Debt Debt-to-Equity Ratio0.27 Current Ratio23.90 Quick Ratio23.90 Sales & Book Value Annual Sales$260,000.00 Price / Sales1,272.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book3.37Miscellaneous Outstanding Shares114,070,000Free Float109,993,000Market Cap$330.80 million OptionableOptionable Beta0.84 Key ExecutivesRobert N. Neville (Age 51)Chairman of the Board, Chief Executive Officer Taneli Jouhikainen (Age 51)President, Chief Operating Officer David L. Lowrance (Age 50)Chief Financial Officer Nevan C. Elam (Age 49)Independent Director Richard J. Hawkins (Age 68)Independent Director Joseph S. McCracken Ph.D. (Age 64)Independent Director Matthew Pauls J.D. (Age 46)Independent Director Yuri Pikover (Age 56)Independent Director More ExecutivesKey CompetitorsAtai Life SciencesNASDAQ:ATAIAstria TherapeuticsNASDAQ:ATXSMacroGenicsNASDAQ:MGNXPrecigenNASDAQ:PGENPrelude TherapeuticsNASDAQ:PRLDView All CompetitorsInsiders & InstitutionsDavid A RamsayBought 37,124 shares on 5/26/2023Total: $97,636.12 ($2.63/share)David A RamsayBought 50,000 shares on 5/24/2023Total: $128,000.00 ($2.56/share)JPMorgan Chase & Co.Bought 34,394 shares on 5/18/2023Ownership: 0.052%Geode Capital Management LLCBought 57,141 shares on 5/16/2023Ownership: 0.940%Balyasny Asset Management L.P.Bought 28,994 shares on 5/16/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions SVRA Stock - Frequently Asked Questions Should I buy or sell Savara stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares. View SVRA analyst ratings or view top-rated stocks. What is Savara's stock price forecast for 2023? 2 Wall Street research analysts have issued 12-month price targets for Savara's stock. Their SVRA share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price. View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts. How have SVRA shares performed in 2023? Savara's stock was trading at $1.55 on January 1st, 2023. Since then, SVRA shares have increased by 87.1% and is now trading at $2.90. View the best growth stocks for 2023 here. When is Savara's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our SVRA earnings forecast. How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) posted its earnings results on Thursday, March, 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP). What is Savara's stock symbol? Savara trades on the NASDAQ under the ticker symbol "SVRA." Who are Savara's major shareholders? Savara's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (9.56%), AXA S.A. (2.48%), Geode Capital Management LLC (0.94%), Sio Capital Management LLC (0.83%), Jane Street Group LLC (0.25%) and Connor Clark & Lunn Investment Management Ltd. (0.18%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken, Matthew Pauls and Raymond Dennis Pratt. View institutional ownership trends. How do I buy shares of Savara? Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Savara's stock price today? One share of SVRA stock can currently be purchased for approximately $2.90. How much money does Savara make? Savara (NASDAQ:SVRA) has a market capitalization of $330.80 million and generates $260,000.00 in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. How can I contact Savara? Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876. This page (NASDAQ:SVRA) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.